Message #83 From:
Stock News Bot Date: April 21, 2008 10:40:58 AM
Nymox Announces Clinical Study Presentation on BPH Drug at American Urological Association Meeting
Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that new
clinical trial data concerning the safety and efficacy of the Company’s
NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the
South Central Section of the American Urological Association Meeting in
San Diego in September. The paper is authored by leading clinical
research investigators participating in the U.S. clinical trials of
NX-1207.
NX-1207 is Nymox’s patented drug candidate for
the treatment of BPH, a common affliction of men related to enlarged
prostate. Blinded clinical trials to date have shown that men treated
with NX-1207 reported statistically significant improvement in BPH
symptoms 3 months after a single NX-1207 treatment with no reported
serious drug-related side effects, including no (0%) significant sexual
side effects. In two multi-center Phase 2 U.S. prospective randomized
blinded clinical trials, the aggregated mean improvement in the Primary
Endpoint of BPH Symptom Score for 2.5 mg NX-1207 was 10.3 points or a
44% improvement in Symptom Score.
Data from the NX02-0016 study (announced by the Company on February 6
and March 11, 2008) showed that NX-1207 markedly reduced the incidence
of nighttime urination (nocturia), a particularly bothersome symptom
associated with BPH. After 90 days, subjects treated with a therapeutic
dose of NX-1207 had a mean reduction in nocturia symptom score of 41%
versus 4% for subjects treated with finasteride, an approved BPH
treatment. This improvement was statistically significant (p<.001).
Having to repeatedly get up in the night to urinate is a common symptom
of BPH that can cause chronic sleep loss and, in turn, lead to fatigue,
memory deficits, mood changes including depression, and increased risk
of long term medical problems.
Results of 5 follow-up studies of available subjects from NX-1207
clinical trials have provided evidence of durable benefits from NX-1207
treatment for up to 3½ years from the date of
treatment.
BPH treatment represents a growing market with more than 100 million men
worldwide being estimated to suffer from BPH symptoms. The disorder is a
common affliction of older men, affecting approximately half of men over
age 50 and close to 90% of men by age 80, and is associated with growth
in prostate size as men age. BPH causes difficulties with urination
associated with aging, such as urination at night, urge to void
frequently, hesitancy, weak stream, and other problems, and can cause
acute urinary retention requiring immediate medical attention.
More information about Nymox is available at www.nymox.com,
email: info@nymox.com, or
800-936-9669.
This press release contains certain “forward-looking
statements” as defined in the United States
Private Securities Litigation Reform Act of 1995 that involve a number
of risks and uncertainties. There can be no assurance that such
statements will prove to be accurate and the actual results and future
events could differ materially from management's current expectations.
The conduct of clinical trials and the development of drug products
involve substantial risks and uncertainties and actual results may
differ materially from expectations. Promising early results do not
ensure that later stage or larger scale clinical trials will be
successful or will proceed as expected. Such factors are detailed from
time to time in Nymox's filings with the United States Securities and
Exchange Commission and other regulatory authorities.
Nymox Pharmaceutical Corporation Roy Wolvin, 800-93NYMOX www.nymox.com
